AssetMark Inc’s Structure Therapeutics GPCR Stock Holding History

AssetMark Inc’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$102K	Buy	3,259 +533	+20%	+$25K	﹤0.01%	1650
2026 Q2	$146K	Buy	2,726 +182	+7%	+$8.05K	﹤0.01%	1526
2026 Q1	$123K	Buy	2,544 +449	+21%	+$30.7K	﹤0.01%	1480
2025 Q4	$146K	Sell	2,095 -289	-12%	-$11.8K	﹤0.01%	1380
2025 Q3	$66.8K	Sell	2,384 -493	-17%	-$9.8K	﹤0.01%	1538
2025 Q2	$59.7K	Buy	2,877 +820	+40%	+$18K	﹤0.01%	1507
2025 Q1	$35.6K	Sell	2,057 -214	-9%	-$5.24K	﹤0.01%	1526
2024 Q4	$61.6K	Buy	2,271 +953	+72%	+$33.8K	﹤0.01%	1368
2024 Q3	$57.8K	Buy	1,318 +719	+120%	+$27.8K	﹤0.01%	1255
2024 Q2	$23.5K	Buy	+599	New	+$24.6K	﹤0.01%	1358

Other funds holding GPCR

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return

Mission Wealth Management Santa Barbara, California $6.32B AUM 20.97% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

AssetMark Inc's GPCR Position: Q3 2026 in Review

AssetMark Inc increased its Structure Therapeutics (GPCR) stake by 20% in Q3 2026, buying an estimated $25K and bringing the position to 3,259 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

AssetMark Inc first reported a position in GPCR in Q2 2024 and has held it in 10 quarters since. The position peaked at $146K in Q2 2026. 22 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

AssetMark Inc held 3,259 shares of Structure Therapeutics worth $102K as of Q3 2026.
AssetMark Inc bought 533 Structure Therapeutics shares in Q3 2026, an estimated $25K.
Structure Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1650 holding.
AssetMark Inc first reported a position in Structure Therapeutics in Q2 2024 and has held it in 10 quarters since.
AssetMark Inc's Structure Therapeutics position peaked at $146K in Q2 2026.
22 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.